NR 566 ADVANCED PHARMACOLOGY CARE OF THE FAMILY
MIDTERM REVIEW 2026/2027 | Latest Chamberlain College
Guide | Pass Guaranteed - A+ Graded
Section: Pharmacokinetics, Pharmacodynamics & Prescribing Foundations
Q1: You're reviewing a medication list for a 67-year-old patient and notice she's taking
both warfarin and fluconazole. Which pharmacokinetic principle best explains why this
combination warrants enhanced INR monitoring?
A. Fluconazole induces CYP2C9, increasing warfarin metabolism
B. Fluconazole inhibits CYP3A4 and CYP2C9, reducing warfarin clearance [CORRECT]
C. Fluconazole displaces warfarin from albumin, increasing volume of distribution
D. Fluconazole enhances renal excretion of warfarin metabolites
Correct Answer: B
Rationale: Fluconazole is a potent inhibitor of both CYP3A4 and CYP2C9—the primary
enzymes responsible for warfarin metabolism. Inhibition reduces clearance, increases
warfarin levels, and elevates bleeding risk. This is a classic example of a drug-drug
interaction requiring proactive monitoring.
● Option A is incorrect because fluconazole inhibits rather than induces these
enzymes; induction would decrease warfarin levels.
● Option C is incorrect because while protein displacement can occur, it's not the
primary mechanism for this interaction, and the effect is typically transient.
● Option D is incorrect because warfarin is hepatically metabolized, not renally
excreted.
,Q2: A patient asks why their phenytoin level keeps fluctuating despite taking the same
dose daily. You explain that phenytoin follows which pharmacokinetic pattern that
makes dosing particularly challenging?
A. First-order elimination with high therapeutic index
B. Zero-order elimination at therapeutic concentrations [CORRECT]
C. Rapid hepatic clearance via phase II glucuronidation
D. Linear pharmacokinetics with predictable accumulation
Correct Answer: B
Rationale: Phenytoin exhibits zero-order (saturation) kinetics at therapeutic
concentrations—meaning enzymes become saturated and small dose changes produce
disproportionate serum level increases. This narrow therapeutic window requires
careful titration and monitoring.
● Option A is incorrect because phenytoin has a narrow therapeutic index, not high,
and follows zero-order rather than first-order kinetics at usual doses.
● Option C is incorrect because phenytoin undergoes phase I hydroxylation (not
phase II glucuronidation) via CYP2C9/2C19.
● Option D is incorrect because phenytoin's pharmacokinetics are nonlinear,
making accumulation unpredictable rather than linear.
Q3: When prescribing for a patient with severe cirrhosis, which factor most significantly
alters drug metabolism and requires dose reduction for hepatically cleared
medications?
A. Decreased plasma protein binding from reduced albumin production
B. Portosystemic shunting bypassing hepatic first-pass metabolism [CORRECT]
C. Increased bile acid synthesis affecting absorption
,D. Enhanced phase II conjugation reactions
Correct Answer: B
Rationale: In severe cirrhosis, portosystemic shunts allow drugs to bypass hepatic
first-pass metabolism, dramatically increasing bioavailability of high-extraction
medications like propranolol or opioids. Combined with reduced hepatocyte function,
this necessitates significant dose reductions.
● Option A is incorrect while protein binding does decrease, this affects distribution
and free drug levels but isn't the primary reason for metabolic dose adjustments.
● Option C is incorrect because bile acid synthesis is actually impaired in cirrhosis,
though this affects lipid absorption more than drug metabolism.
● Option D is incorrect because phase II reactions are generally preserved longer
than phase I in liver disease, not enhanced.
Q4: Which statement accurately describes the relationship between a drug's half-life and
time to steady state?
A. Steady state is achieved in approximately one half-life
B. Steady state requires approximately three half-lives
C. Steady state is reached in approximately five half-lives [CORRECT]
D. Steady state occurs immediately with continuous infusion
Correct Answer: C
Rationale: Pharmacokinetic principles establish that 97% of steady-state concentration
is achieved after five half-lives, making this the clinical standard for timing therapeutic
drug monitoring or assessing efficacy when initiating chronic therapy.
● Option A is incorrect because after one half-life, only 50% of steady-state is
reached.
, ● Option B is incorrect because three half-lives achieves only 87.5% of
steady-state—adequate for some drugs but not sufficient for narrow therapeutic
index medications.
● Option D is incorrect because even with continuous infusion, accumulation
follows half-life kinetics rather than occurring immediately.
Q5: You're caring for a 78-year-old patient with heart failure who recently started St.
John's wort for depression. Which of their chronic medications is most likely to have
reduced efficacy due to this herbal supplement?
A. Digoxin
B. Furosemide
C. Atorvastatin
D. Lisinopril
Correct Answer: A
Rationale: St. John's wort is a potent CYP3A4 inducer and P-glycoprotein inducer.
Digoxin is a P-glycoprotein substrate, and induction increases its clearance, potentially
causing subtherapeutic levels and worsening heart failure control.
● Option B is incorrect because furosemide's efficacy depends on renal perfusion
and tubular secretion, not significantly affected by CYP450 induction.
● Option C is incorrect while atorvastatin is CYP3A4 substrate, the primary concern
with St. John's wort is actually reduced efficacy of drugs like oral contraceptives,
warfarin, and digoxin; though levels may decrease, digoxin has the narrower
therapeutic window.
● Option D is incorrect because lisinopril is renally excreted unchanged and not
significantly metabolized by CYP450 enzymes.
Q6: A patient with anxiety is prescribed lorazepam 1mg TID. Which pharmacokinetic
property makes lorazepam generally preferable to diazepam for elderly patients
requiring anxiolytic therapy?
MIDTERM REVIEW 2026/2027 | Latest Chamberlain College
Guide | Pass Guaranteed - A+ Graded
Section: Pharmacokinetics, Pharmacodynamics & Prescribing Foundations
Q1: You're reviewing a medication list for a 67-year-old patient and notice she's taking
both warfarin and fluconazole. Which pharmacokinetic principle best explains why this
combination warrants enhanced INR monitoring?
A. Fluconazole induces CYP2C9, increasing warfarin metabolism
B. Fluconazole inhibits CYP3A4 and CYP2C9, reducing warfarin clearance [CORRECT]
C. Fluconazole displaces warfarin from albumin, increasing volume of distribution
D. Fluconazole enhances renal excretion of warfarin metabolites
Correct Answer: B
Rationale: Fluconazole is a potent inhibitor of both CYP3A4 and CYP2C9—the primary
enzymes responsible for warfarin metabolism. Inhibition reduces clearance, increases
warfarin levels, and elevates bleeding risk. This is a classic example of a drug-drug
interaction requiring proactive monitoring.
● Option A is incorrect because fluconazole inhibits rather than induces these
enzymes; induction would decrease warfarin levels.
● Option C is incorrect because while protein displacement can occur, it's not the
primary mechanism for this interaction, and the effect is typically transient.
● Option D is incorrect because warfarin is hepatically metabolized, not renally
excreted.
,Q2: A patient asks why their phenytoin level keeps fluctuating despite taking the same
dose daily. You explain that phenytoin follows which pharmacokinetic pattern that
makes dosing particularly challenging?
A. First-order elimination with high therapeutic index
B. Zero-order elimination at therapeutic concentrations [CORRECT]
C. Rapid hepatic clearance via phase II glucuronidation
D. Linear pharmacokinetics with predictable accumulation
Correct Answer: B
Rationale: Phenytoin exhibits zero-order (saturation) kinetics at therapeutic
concentrations—meaning enzymes become saturated and small dose changes produce
disproportionate serum level increases. This narrow therapeutic window requires
careful titration and monitoring.
● Option A is incorrect because phenytoin has a narrow therapeutic index, not high,
and follows zero-order rather than first-order kinetics at usual doses.
● Option C is incorrect because phenytoin undergoes phase I hydroxylation (not
phase II glucuronidation) via CYP2C9/2C19.
● Option D is incorrect because phenytoin's pharmacokinetics are nonlinear,
making accumulation unpredictable rather than linear.
Q3: When prescribing for a patient with severe cirrhosis, which factor most significantly
alters drug metabolism and requires dose reduction for hepatically cleared
medications?
A. Decreased plasma protein binding from reduced albumin production
B. Portosystemic shunting bypassing hepatic first-pass metabolism [CORRECT]
C. Increased bile acid synthesis affecting absorption
,D. Enhanced phase II conjugation reactions
Correct Answer: B
Rationale: In severe cirrhosis, portosystemic shunts allow drugs to bypass hepatic
first-pass metabolism, dramatically increasing bioavailability of high-extraction
medications like propranolol or opioids. Combined with reduced hepatocyte function,
this necessitates significant dose reductions.
● Option A is incorrect while protein binding does decrease, this affects distribution
and free drug levels but isn't the primary reason for metabolic dose adjustments.
● Option C is incorrect because bile acid synthesis is actually impaired in cirrhosis,
though this affects lipid absorption more than drug metabolism.
● Option D is incorrect because phase II reactions are generally preserved longer
than phase I in liver disease, not enhanced.
Q4: Which statement accurately describes the relationship between a drug's half-life and
time to steady state?
A. Steady state is achieved in approximately one half-life
B. Steady state requires approximately three half-lives
C. Steady state is reached in approximately five half-lives [CORRECT]
D. Steady state occurs immediately with continuous infusion
Correct Answer: C
Rationale: Pharmacokinetic principles establish that 97% of steady-state concentration
is achieved after five half-lives, making this the clinical standard for timing therapeutic
drug monitoring or assessing efficacy when initiating chronic therapy.
● Option A is incorrect because after one half-life, only 50% of steady-state is
reached.
, ● Option B is incorrect because three half-lives achieves only 87.5% of
steady-state—adequate for some drugs but not sufficient for narrow therapeutic
index medications.
● Option D is incorrect because even with continuous infusion, accumulation
follows half-life kinetics rather than occurring immediately.
Q5: You're caring for a 78-year-old patient with heart failure who recently started St.
John's wort for depression. Which of their chronic medications is most likely to have
reduced efficacy due to this herbal supplement?
A. Digoxin
B. Furosemide
C. Atorvastatin
D. Lisinopril
Correct Answer: A
Rationale: St. John's wort is a potent CYP3A4 inducer and P-glycoprotein inducer.
Digoxin is a P-glycoprotein substrate, and induction increases its clearance, potentially
causing subtherapeutic levels and worsening heart failure control.
● Option B is incorrect because furosemide's efficacy depends on renal perfusion
and tubular secretion, not significantly affected by CYP450 induction.
● Option C is incorrect while atorvastatin is CYP3A4 substrate, the primary concern
with St. John's wort is actually reduced efficacy of drugs like oral contraceptives,
warfarin, and digoxin; though levels may decrease, digoxin has the narrower
therapeutic window.
● Option D is incorrect because lisinopril is renally excreted unchanged and not
significantly metabolized by CYP450 enzymes.
Q6: A patient with anxiety is prescribed lorazepam 1mg TID. Which pharmacokinetic
property makes lorazepam generally preferable to diazepam for elderly patients
requiring anxiolytic therapy?
